PXMD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms...

Stats
Today's Volume	494 828
Average Volume	2.41M
Market Cap	5.52M
EPS	$-1.450 ( 2024-04-03 )
Next earnings date	( $-0.430 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0700
ATR14	$0.00900 (1.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Weisman Howard J.	Sell	2 927	Common Stock
2024-03-12	Sheldon Stephen	Sell	3 356	Common Stock
2024-03-12	Rome Zachary	Sell	4 904	Common Stock
2024-03-12	Larochelle Karen	Sell	604	Common Stock
2024-03-12	Hough David W.	Sell	1 452	Common Stock

INSIDER POWER
20.40
Last 97 transactions
Buy: 1 048 583 \| Sell: 546 215

Volume Correlation

Long: -0.27 (neutral)

Short: 0.30 (neutral)

Signal:(48.323) Neutral

PaxMedica, Inc. Common Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PaxMedica, Inc. Common Correlation - Currency/Commodity

0.21
( neutral )

0.38
( neutral )

0.00
( neutral )

-0.31
( neutral )

PaxMedica, Inc. Common Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-11.00

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-11.00

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-26.83

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.021

Financial Reports:

No articles found.

PaxMedica, Inc. Common

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.